Vemurafenib provided meaningful clinical benefit to Spanish patients with BRAF V600 mutation-positive metastatic melanoma

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • Vemurafenib is beneficial in patients with BRAF V600 mutation-positive metastatic melanoma, including older patients and those with comorbidities, brain involvement, and poor performance status—a population representative of patients seen in real-life clinical practice.
Study design
  • A...